Metastatic Colorectal Cancer - Pipeline Review, H2 2015


#553608

690pages

Global Markets Direct

$ 2000

In Stock

Metastatic Colorectal Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Metastatic Colorectal Cancer - Pipeline Review, H2 2015, provides an overview of the Metastatic Colorectal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Colorectal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Colorectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 7
Metastatic Colorectal Cancer Overview 8
Therapeutics Development 9
Metastatic Colorectal Cancer - Therapeutics under Development by Companies 11
Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 18
Metastatic Colorectal Cancer - Pipeline Products Glance 19
Metastatic Colorectal Cancer - Products under Development by Companies 23
Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes 31
Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development 32
Metastatic Colorectal Cancer - Therapeutics Assessment 117
Drug Profiles 139
Metastatic Colorectal Cancer - Recent Pipeline Updates 426
Metastatic Colorectal Cancer - Dormant Projects 656
Metastatic Colorectal Cancer - Discontinued Products 663
Metastatic Colorectal Cancer - Product Development Milestones 666
Appendix 675

List of Tables
Number of Products under Development for Metastatic Colorectal Cancer, H2 2015 23
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H2 2015 24
Number of Products under Development by Companies, H2 2015 26
Number of Products under Development by Companies, H2 2015 (Contd..1) 27
Number of Products under Development by Companies, H2 2015 (Contd..2) 28
Number of Products under Development by Companies, H2 2015 (Contd..3) 29
Number of Products under Development by Companies, H2 2015 (Contd..4) 30
Number of Products under Development by Companies, H2 2015 (Contd..5) 31
Number of Products under Investigation by Universities/Institutes, H2 2015 32
Comparative Analysis by Late Stage Development, H2 2015 33
Comparative Analysis by Clinical Stage Development, H2 2015 34
Comparative Analysis by Early Stage Development, H2 2015 35
Comparative Analysis by Unknown Stage Development, H2 2015 36
Products under Development by Companies, H2 2015 37
Products under Development by Companies, H2 2015 (Contd..1) 38
Products under Development by Companies, H2 2015 (Contd..2) 39
Products under Development by Companies, H2 2015 (Contd..3) 40
Products under Development by Companies, H2 2015 (Contd..4) 41
Products under Development by Companies, H2 2015 (Contd..5) 42
Products under Development by Companies, H2 2015 (Contd..6) 43
Products under Development by Companies, H2 2015 (Contd..7) 44
Products under Investigation by Universities/Institutes, H2 2015 45
Metastatic Colorectal Cancer - Pipeline by AB Science SA, H2 2015 46
Metastatic Colorectal Cancer - Pipeline by AbbVie Inc., H2 2015 47
Metastatic Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 48
Metastatic Colorectal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015 49
Metastatic Colorectal Cancer - Pipeline by Alchemia Limited, H2 2015 50
Metastatic Colorectal Cancer - Pipeline by Amgen Inc., H2 2015 51
Metastatic Colorectal Cancer - Pipeline by Apexigen, Inc., H2 2015 52
Metastatic Colorectal Cancer - Pipeline by ArQule, Inc., H2 2015 53
Metastatic Colorectal Cancer - Pipeline by Array BioPharma Inc., H2 2015 54
Metastatic Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 55
Metastatic Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2015 56
Metastatic Colorectal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 57
Metastatic Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2015 58
Metastatic Colorectal Cancer - Pipeline by Baxalta Incorporated, H2 2015 59
Metastatic Colorectal Cancer - Pipeline by Bayer AG, H2 2015 60
Metastatic Colorectal Cancer - Pipeline by Biocon Limited, H2 2015 61
Metastatic Colorectal Cancer - Pipeline by Bionovis SA, H2 2015 62
Metastatic Colorectal Cancer - Pipeline by Biothera, Inc., H2 2015 63
Metastatic Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 64
Metastatic Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015 65
Metastatic Colorectal Cancer - Pipeline by Celgene Corporation, H2 2015 66
Metastatic Colorectal Cancer - Pipeline by Celltrion, Inc., H2 2015 67
Metastatic Colorectal Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2015 68
Metastatic Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015 69
Metastatic Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H2 2015 70
Metastatic Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 71
Metastatic Colorectal Cancer - Pipeline by EirGenix Inc., H2 2015 72
Metastatic Colorectal Cancer - Pipeline by Eisai Co., Ltd., H2 2015 73
Metastatic Colorectal Cancer - Pipeline by Eli Lilly and Company, H2 2015 74
Metastatic Colorectal Cancer - Pipeline by EnGeneIC Ltd, H2 2015 75
Metastatic Colorectal Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 76
Metastatic Colorectal Cancer - Pipeline by Etubics Corporation, H2 2015 77
Metastatic Colorectal Cancer - Pipeline by Exelixis, Inc., H2 2015 78
Metastatic Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 79
Metastatic Colorectal Cancer - Pipeline by Genentech, Inc., H2 2015 80
Metastatic Colorectal Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2015 81
Metastatic Colorectal Cancer - Pipeline by Glycotope GmbH, H2 2015 82
Metastatic Colorectal Cancer - Pipeline by Hetero Drugs Limited, H2 2015 83
Metastatic Colorectal Cancer - Pipeline by Hospira, Inc., H2 2015 84
Metastatic Colorectal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015 85
Metastatic Colorectal Cancer - Pipeline by Ignyta, Inc., H2 2015 86
Metastatic Colorectal Cancer - Pipeline by immatics biotechnologies GmbH, H2 2015 87
Metastatic Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2015 88
Metastatic Colorectal Cancer - Pipeline by Immunomedics, Inc., H2 2015 89
Metastatic Colorectal Cancer - Pipeline by Immunovative Therapies, Ltd., H2 2015 90
Metastatic Colorectal Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 91
Metastatic Colorectal Cancer - Pipeline by Incyte Corporation, H2 2015 92
Metastatic Colorectal Cancer - Pipeline by Kadmon Corporation, LLC, H2 2015 93
Metastatic Colorectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 94
Metastatic Colorectal Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 95
Metastatic Colorectal Cancer - Pipeline by Mabion SA, H2 2015 96
Metastatic Colorectal Cancer - Pipeline by Mabtech Limited, H2 2015 97
Metastatic Colorectal Cancer - Pipeline by mAbxience S.A., H2 2015 98
Metastatic Colorectal Cancer - Pipeline by MacroGenics, Inc., H2 2015 99
Metastatic Colorectal Cancer - Pipeline by MedImmune, LLC, H2 2015 100
Metastatic Colorectal Cancer - Pipeline by Medivation, Inc., H2 2015 101
Metastatic Colorectal Cancer - Pipeline by Merck & Co., Inc., H2 2015 102
Metastatic Colorectal Cancer - Pipeline by Merck KGaA, H2 2015 103
Metastatic Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015 104
Metastatic Colorectal Cancer - Pipeline by Merus B.V., H2 2015 105
Metastatic Colorectal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 106
Metastatic Colorectal Cancer - Pipeline by MolMed S.p.A., H2 2015 107
Metastatic Colorectal Cancer - Pipeline by Mologen AG, H2 2015 108
Metastatic Colorectal Cancer - Pipeline by Morphotek, Inc., H2 2015 109
Metastatic Colorectal Cancer - Pipeline by Mycenax Biotech Inc., H2 2015 110
Metastatic Colorectal Cancer - Pipeline by Natco Pharma Limited, H2 2015 111
Metastatic Colorectal Cancer - Pipeline by Nektar Therapeutics, H2 2015 112
Metastatic Colorectal Cancer - Pipeline by Nippon Kayaku Co., Ltd., H2 2015 113
Metastatic Colorectal Cancer - Pipeline by Novartis AG, H2 2015 114
Metastatic Colorectal Cancer - Pipeline by OBI Pharma, Inc., H2 2015 115
Metastatic Colorectal Cancer - Pipeline by Oncobiologics, Inc., H2 2015 116
Metastatic Colorectal Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015 117
Metastatic Colorectal Cancer - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 118
Metastatic Colorectal Cancer - Pipeline by Panacea Biotec Limited, H2 2015 119
Metastatic Colorectal Cancer - Pipeline by Pfizer Inc., H2 2015 120
Metastatic Colorectal Cancer - Pipeline by Pharma Mar, S.A., H2 2015 121
Metastatic Colorectal Cancer - Pipeline by Pharmacyclics, Inc., H2 2015 122
Metastatic Colorectal Cancer - Pipeline by Precision Biologics, Inc., H2 2015 123
Metastatic Colorectal Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2015 124
Metastatic Colorectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 125
Metastatic Colorectal Cancer - Pipeline by Sillajen Biotherapeutics, H2 2015 126
Metastatic Colorectal Cancer - Pipeline by Symphogen A/S, H2 2015 127
Metastatic Colorectal Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015 128
Metastatic Colorectal Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2015 129
Metastatic Colorectal Cancer - Pipeline by Verlyx Pharma Inc., H2 2015 130
Assessment by Monotherapy Products, H2 2015 131
Assessment by Combination Products, H2 2015 132
Number of Products by Stage and Target, H2 2015 134
Number of Products by Stage and Mechanism of Action, H2 2015 143
Number of Products by Stage and Route of Administration, H2 2015 150
Number of Products by Stage and Molecule Type, H2 2015 152
Metastatic Colorectal Cancer Therapeutics - Recent Pipeline Updates, H2 2015 440
Metastatic Colorectal Cancer - Dormant Projects, H2 2015 670
Metastatic Colorectal Cancer - Dormant Projects (Contd..1), H2 2015 671
Metastatic Colorectal Cancer - Dormant Projects (Contd..2), H2 2015 672
Metastatic Colorectal Cancer - Dormant Projects (Contd..3), H2 2015 673
Metastatic Colorectal Cancer - Dormant Projects (Contd..4), H2 2015 674
Metastatic Colorectal Cancer - Dormant Projects (Contd..5), H2 2015 675
Metastatic Colorectal Cancer - Dormant Projects (Contd..6), H2 2015 676
Metastatic Colorectal Cancer - Discontinued Products, H2 2015 677
Metastatic Colorectal Cancer - Discontinued Products (Contd..1), H2 2015 678
Metastatic Colorectal Cancer - Discontinued Products (Contd..2), H2 2015 679

List of Figures
Number of Products under Development for Metastatic Colorectal Cancer, H2 2015 23
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H2 2015 24
Number of Products under Development by Companies, H2 2015 25
Number of Products under Investigation by Universities/Institutes, H2 2015 32
Comparative Analysis by Late Stage Development, H2 2015 33
Comparative Analysis by Clinical Stage Development, H2 2015 34
Comparative Analysis by Early Stage Products, H2 2015 35
Assessment by Monotherapy Products, H2 2015 131
Assessment by Combination Products, H2 2015 132
Number of Products by Top 10 Targets, H2 2015 133
Number of Products by Stage and Top 10 Targets, H2 2015 133
Number of Products by Top 10 Mechanism of Actions, H2 2015 142
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 142
Number of Products by Top 10 Routes of Administration, H2 2015 149
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 149
Number of Products by Top 10 Molecule Types, H2 2015 151
Number of Products by Stage and Top 10 Molecule Types, H2 2015 151